Supportive care
Phase 3Small molecule
BeiGeneSupportive care is one of 66 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
92 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Glypressin
MMallinckrodt
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Oraverse
LLife Extension Foundation Inc.
Phase 3
Northera
LundbeckPhase 2
Lamisil
NovartisPhase 2
Desferal
Jazz PharmaceuticalsPhase 2
Pitressin
AAultman Health Foundation
Phase 2
Arginine Vasopressin
SStanford University
Phase 3
Jardiance
Boehringer IngelheimPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Respiratory Distress Syndrome1 trial
COVID-191 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Supportive care. EMBL-EBI & Wellcome Sanger Institute.
- [4]